https://www.pharmaradar360.com/article/biogen-bets-newly-acquired-apellis-can-paper-over-leqembi-s-disappointing-sales-ada1a4a62fcc3389Pharma Surgeen2026-07-23T14:00:00.000ZBiogen bets newly acquired Apellis can paper over Leqembi's disappointing sales into 2027https://www.pharmaradar360.com/article/intrepidx-adds-hatch-waxman-ediscovery-leader-taylor-judd-to-expand-pharmaceutic-b68a91c47a365b58Pharma Surgeen2026-07-23T14:00:00.000ZIntrepidX Adds Hatch-Waxman eDiscovery Leader Taylor Judd to Expand Pharmaceutical Litigation and Corporate Legal Growthhttps://www.pharmaradar360.com/article/an-ai-biotech-just-reported-a-46-revenue-jump-and-its-first-recurring-platform-c-023e85cd51d07940Pharma Surgeen2026-07-23T13:53:09.000ZAn AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbershttps://www.pharmaradar360.com/article/artigo-o-verdadeiro-valor-da-inovacao-esta-na-jornada-do-paciente-3628d30617469bc8Pharma Surgeen2026-07-23T13:52:32.000ZArtigo: O verdadeiro valor da inovação está na jornada do pacientehttps://www.pharmaradar360.com/article/lilly-s-triple-agonist-retatrutide-successful-in-two-additional-phase-3-obesity-92d171b90ccb71cfPharma Surgeen2026-07-23T13:51:24.000ZLilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trialshttps://www.pharmaradar360.com/article/earnings-call-transcript-west-pharmaceutical-beats-q2-2026-estimates-lifts-outlo-b7ebaa88e892ea4aPharma Surgeen2026-07-23T13:42:05.000ZEarnings call transcript: West Pharmaceutical beats Q2 2026 estimates, lifts outlookhttps://www.pharmaradar360.com/article/seven-peptides-are-being-reviewed-by-an-fda-panel-here-s-what-to-know-cc1cdb16df7c1d96Pharma Surgeen2026-07-23T13:32:10.000ZSeven peptides are being reviewed by an FDA panel. Here’s what to know.https://www.pharmaradar360.com/article/egyptian-biotech-reme-d-raises-usd-1-45-m-pre-series-a-to-expand-molecular-diagn-59d69c2c84ae0174Pharma Surgeen2026-07-23T13:20:32.000ZEgyptian Biotech Reme-D Raises USD 1.45 M Pre-Series A To Expand Molecular Diagnosticshttps://www.pharmaradar360.com/article/what-to-know-about-the-7-peptides-being-reviewed-by-an-fda-panel-8985159c9a97ef8bPharma Surgeen2026-07-23T13:13:22.000ZWhat to know about the 7 peptides being reviewed by an FDA panelhttps://www.pharmaradar360.com/article/eli-lilly-is-acquiring-a-psychedelic-medicine-biotech-here-s-what-you-need-to-kn-029261212a25f35ePharma Surgeen2026-07-23T13:09:30.000ZEli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here's What You Need to Know.https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-2026-to-2027-46b78a2386536090Pharma Surgeen2026-07-23T13:00:07.000ZWeekly all-cause mortality surveillance: 2026 to 2027https://www.pharmaradar360.com/article/syndromic-surveillance-weekly-summaries-for-2026-45747e3878253defPharma Surgeen2026-07-23T13:00:07.000ZSyndromic surveillance: weekly summaries for 2026https://www.pharmaradar360.com/article/remote-health-advice-weekly-bulletins-for-2026-0b8fbceac342c05cPharma Surgeen2026-07-23T13:00:07.000ZRemote health advice: weekly bulletins for 2026https://www.pharmaradar360.com/article/national-ambulance-syndromic-surveillance-weekly-bulletins-2026-6dee157afd1fba75Pharma Surgeen2026-07-23T13:00:07.000ZNational ambulance syndromic surveillance: weekly bulletins 2026https://www.pharmaradar360.com/article/gp-out-of-hours-syndromic-surveillance-weekly-bulletins-for-2026-f212a5a75078c06ePharma Surgeen2026-07-23T13:00:07.000ZGP out-of-hours syndromic surveillance: weekly bulletins for 2026https://www.pharmaradar360.com/article/gp-in-hours-weekly-bulletins-for-2026-dfebf391f225843dPharma Surgeen2026-07-23T13:00:07.000ZGP in-hours: weekly bulletins for 2026https://www.pharmaradar360.com/article/emergency-department-weekly-bulletins-for-2026-08abcdde2881ef86Pharma Surgeen2026-07-23T13:00:07.000ZEmergency department: weekly bulletins for 2026https://www.pharmaradar360.com/article/level-of-attention-and-its-effects-on-risk-of-confusion-and-dilution-recent-eu-c-fb03f58c3fa5b78cPharma Surgeen2026-07-23T12:55:02.000ZLevel of attention and its effects on risk of confusion and dilution: recent EU case lawhttps://www.pharmaradar360.com/article/guidance-clinical-investigations-compiling-a-submission-b0150003dcab6d8fPharma Surgeen2026-07-23T12:43:36.000ZGuidance: Clinical investigations: compiling a submissionhttps://www.pharmaradar360.com/article/guidance-medical-devices-that-need-a-clinical-investigation-517dcad73a93591bPharma Surgeen2026-07-23T12:43:35.000ZGuidance: Medical devices that need a clinical investigationhttps://www.pharmaradar360.com/article/clinical-investigations-for-medical-devices-523f464bba1e6999Pharma Surgeen2026-07-23T12:43:34.000ZClinical investigations for medical deviceshttps://www.pharmaradar360.com/article/clinical-investigations-in-great-britain-e605b885c65902e1Pharma Surgeen2026-07-23T12:43:34.000ZClinical investigations in Great Britainhttps://www.pharmaradar360.com/article/guidance-approving-clinical-investigations-fa912ac542fa3debPharma Surgeen2026-07-23T12:43:33.000ZGuidance: Approving clinical investigationshttps://www.pharmaradar360.com/article/us-fda-panel-weighs-injectable-peptides-as-experts-demand-gray-market-guardrails-7f060c1025dcd114Pharma Surgeen2026-07-23T12:41:41.000ZUS FDA panel weighs injectable peptides as experts demand gray market guardrailshttps://www.pharmaradar360.com/article/boletin-sobre-productos-sanitarios-abril-junio-2026-734efc373548e49cPharma Surgeen2026-07-23T12:34:21.000ZBoletín sobre Productos Sanitarios. Abril – junio 2026https://www.pharmaradar360.com/article/la-aemps-informa-de-la-deteccion-de-unidades-falsificadas-del-producto-cosmetico-9299b92adffd2de3Pharma Surgeen2026-07-23T12:27:02.000ZLa AEMPS informa de la detección de unidades falsificadas del producto cosmético Xhekpon cremahttps://www.pharmaradar360.com/article/west-pharmaceutical-services-nyse-wst-beats-expectations-in-strong-q2-cy2026-sto-9d3d4ff30a5e3019Pharma Surgeen2026-07-23T12:25:19.000ZWest Pharmaceutical Services (NYSE:WST) Beats Expectations in Strong Q2 CY2026, Stock Soarshttps://www.pharmaradar360.com/article/west-pharmaceutical-services-releases-q2-2026-financial-results-061c87153992c7cdPharma Surgeen2026-07-23T12:19:20.000ZWest Pharmaceutical Services Releases Q2 2026 Financial Resultshttps://www.pharmaradar360.com/article/which-ishares-healthcare-etf-is-the-better-buy-diversified-ixj-or-biotech-focuse-0b699d2b7449f068Pharma Surgeen2026-07-23T12:18:10.000ZWhich iShares Healthcare ETF Is the Better Buy: Diversified IXJ or Biotech-Focused IBB?https://www.pharmaradar360.com/article/gerd-affects-about-20-of-u-s-population-as-jaqbo-nears-phase-3-884908e3091f5a34Pharma Surgeen2026-07-23T12:15:00.000ZGERD affects about 20% of U.S. population as JAQBO nears Phase 3https://www.pharmaradar360.com/article/roche-diagnostics-growth-remains-muted-amid-china-headwinds-abf569d3f7180e62Pharma Surgeen2026-07-23T12:13:47.000ZRoche Diagnostics growth remains muted amid China headwindshttps://www.pharmaradar360.com/article/veraxa-biotech-names-christoph-erkel-as-chief-scientific-officer-8c326dda085c27c2Pharma Surgeen2026-07-23T12:04:39.000ZVeraxa Biotech names Christoph Erkel as chief scientific officerhttps://www.pharmaradar360.com/article/is-west-pharmaceutical-services-inc-wst-undervalued-after-q2-e-eb79f472e4aa3590Pharma Surgeen2026-07-23T12:01:04.000ZIs West Pharmaceutical Services Inc (WST) Undervalued After Q2 Ehttps://www.pharmaradar360.com/article/heartsine-samaritan-pad-sam-350p-sam-360p-sam-500p-membrane-tail-fff5a5c17128f0b3Pharma Surgeen2026-07-23T12:00:00.000ZHeartSine® Samaritan® PAD SAM 350P/SAM 360P/SAM 500P - Membrane Tailhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-nyse-wst-beats-expectations-in-strong-q2-cy2026-sto-18d05d3d219f8503Pharma Surgeen2026-07-23T11:58:00.000ZWest Pharmaceutical Services (NYSE:WST) Beats Expectations in Strong Q2 CY2026, Stock Soarshttps://www.pharmaradar360.com/article/h-c-wainwright-reiterates-arrowhead-pharma-stock-rating-on-trial-data-477eaed4efa21a08Pharma Surgeen2026-07-23T11:58:00.000ZH.C. Wainwright reiterates Arrowhead Pharma stock rating on trial datahttps://www.pharmaradar360.com/article/la-aemps-inicia-los-ipt-de-los-medicamentos-que-han-obtenido-una-opinion-positiv-f84c630bbc1336e4Pharma Surgeen2026-07-23T11:57:24.000ZLa AEMPS inicia los IPT de los medicamentos que han obtenido una opinión positiva en la reunión del CHMP celebrada en juniohttps://www.pharmaradar360.com/article/la-aemps-inicia-los-ipt-de-los-medicamentos-que-han-obtenido-una-opinion-positiv-5de4fe4b69618dc0Pharma Surgeen2026-07-23T11:55:38.000ZLa AEMPS inicia los IPT de los medicamentos que han obtenido una opinión positiva en la reunión del CHMP celebrada en mayohttps://www.pharmaradar360.com/article/everything-you-need-to-know-about-clinical-trial-legislation-changes-afe49a912db358d5Pharma Surgeen2026-07-23T11:19:06.000ZEverything you need to know about clinical trial legislation changeshttps://www.pharmaradar360.com/article/biotech-stocks-lead-healthcare-s-overbought-list-as-earnings-picks-up-xlv-nysear-174f73b5ab81bbe6Pharma Surgeen2026-07-23T11:18:04.000ZBiotech stocks lead healthcare's overbought list as earnings picks up (XLV:NYSEARCA)https://www.pharmaradar360.com/article/form-8-k-west-pharmaceutical-serv-for-jul-23-1a75904bff342352Pharma Surgeen2026-07-23T11:16:25.000ZForm 8-K WEST PHARMACEUTICAL SERV For: Jul 23https://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-q2-earnings-and-revenues-top-estimates-8ca265920e2f862aPharma Surgeen2026-07-23T11:15:04.000ZWest Pharmaceutical Services (WST) Q2 Earnings and Revenues Top Estimateshttps://www.pharmaradar360.com/article/veraxa-biotech-ag-appoints-christoph-erkel-ph-d-as-chief-scientific-officer-12a0226fae797c9cPharma Surgeen2026-07-23T11:12:00.000ZVERAXA Biotech AG Appoints Christoph Erkel, Ph.D., as Chief Scientific Officerhttps://www.pharmaradar360.com/article/rabies-post-exposure-risk-assessment-form-and-calendar-f8033f746394b277Pharma Surgeen2026-07-23T11:11:31.000ZRabies post exposure risk assessment form and calendarhttps://www.pharmaradar360.com/article/when-compounding-goes-bad-people-pay-the-price-9aad62a2ead0af1cPharma Surgeen2026-07-23T11:10:14.000ZWhen Compounding Goes Bad, People Pay the Pricehttps://www.pharmaradar360.com/article/sartorius-stedim-biotech-buy-rating-from-rbc-0a03a4ab636037c7Pharma Surgeen2026-07-23T11:06:22.000ZSARTORIUS STEDIM BIOTECH : Buy rating from RBChttps://www.pharmaradar360.com/article/price-to-sales-forward-of-hyundai-pharmaceutical-co-ltd-krx-004310-004a6a4b5e95c5acPharma Surgeen2026-07-23T11:02:20.000ZPrice to sales forward of Hyundai Pharmaceutical Co., Ltd. – KRX:004310https://www.pharmaradar360.com/article/okyo-pharma-nasdaq-okyo-ceo-purchases-15-000-company-shares-2c3efab827bb6be0Pharma Surgeen2026-07-23T11:00:42.000ZOKYO Pharma (Nasdaq: OKYO) CEO purchases 15,000 company shareshttps://www.pharmaradar360.com/article/okyo-pharma-plans-global-phase-3-trial-for-about-111-patients-689a08b050099e2fPharma Surgeen2026-07-23T11:00:00.000ZOKYO Pharma Plans Global Phase 3 Trial for About 111 Patientshttps://www.pharmaradar360.com/article/lilly-s-triple-agonist-retatrutide-successful-in-two-additional-phase-3-obesity-f2ad33ed10f44d10Pharma Surgeen2026-07-23T10:45:00.000ZLilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1Chttps://www.pharmaradar360.com/article/eli-lilly-s-next-gen-obesity-drug-clears-phase-3-trials-but-heart-benefits-remai-27b79f270d007e8ePharma Surgeen2026-07-23T10:45:00.000ZEli Lilly’s Next-Gen Obesity Drug Clears Phase 3 Trials, But Heart Benefits Remain Unprovenhttps://www.pharmaradar360.com/article/lilly-s-triple-agonist-retatrutide-successful-in-two-additional-phase-3-obesity-401e431d29f58515Pharma Surgeen2026-07-23T10:45:00.000ZLilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1Chttps://www.pharmaradar360.com/article/mabion-and-krisan-biotech-launch-partnership-for-next-gen-adcs-7a47cc1e0abcf982Pharma Surgeen2026-07-23T10:38:26.000ZMabion and KriSan Biotech Launch Partnership for Next-Gen ADCshttps://www.pharmaradar360.com/article/west-pharmaceutical-raises-annual-profit-forecast-on-strong-demand-for-injectabl-6e8d5efac628275dPharma Surgeen2026-07-23T10:37:38.000ZWest Pharmaceutical raises annual profit forecast on strong demand for injectable drug componentshttps://www.pharmaradar360.com/article/initiate-prioritizes-early-stage-biotech-startups-with-proprietary-data-over-ai-0081d6cc8944f84aPharma Surgeen2026-07-23T10:36:26.000ZInitiate Prioritizes Early-Stage Biotech Startups With Proprietary Data Over AI Modelshttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-jiangsu-lianhuan-pharmaceutical-co-ltd-class-860037b1338ff2e2Pharma Surgeen2026-07-23T10:31:06.000ZEnterprise value to EBIT forward of Jiangsu Lianhuan Pharmaceutical Co., Ltd. Class A – SSE:600513https://www.pharmaradar360.com/article/obesity-biotech-verdiva-hires-ex-metsera-cmo-as-crucial-readouts-approach-dae9608479a5f1d9Pharma Surgeen2026-07-23T10:30:00.000ZObesity biotech Verdiva hires ex-Metsera CMO as crucial readouts approachhttps://www.pharmaradar360.com/article/wst-west-pharmaceutical-services-inc-expects-q3-revenue-range-820-0m-835-0m-a8db3c4b8c169a81Pharma Surgeen2026-07-23T10:28:20.000Z(WST) West Pharmaceutical Services, Inc. Expects Q3 Revenue Range $820.0M - $835.0Mhttps://www.pharmaradar360.com/article/wst-west-pharmaceutical-services-expects-full-year-2026-adjusted-eps-range-8-85-92911e9a0c2b678ePharma Surgeen2026-07-23T10:27:26.000Z(WST) West Pharmaceutical Services Expects Full Year 2026 Adjusted EPS Range $8.85 - $9.05, vs. FactSet Est of $8.62https://www.pharmaradar360.com/article/earnings-flash-wst-west-pharmaceutical-services-inc-reports-q2-revenue-872-3m-vs-9122ad898aeb027ePharma Surgeen2026-07-23T10:26:55.000ZEarnings Flash (WST) West Pharmaceutical Services, Inc. Reports Q2 Revenue $872.3M, vs. FactSet Est of $840.0Mhttps://www.pharmaradar360.com/article/earnings-flash-wst-west-pharmaceutical-services-inc-posts-q2-adjusted-eps-2-37-p-77f2459e16724cb1Pharma Surgeen2026-07-23T10:25:51.000ZEarnings Flash (WST) West Pharmaceutical Services, Inc. Posts Q2 Adjusted EPS $2.37 per Share, vs. FactSet Est of $2.08https://www.pharmaradar360.com/article/militia-capital-management-llc-takes-3-50-million-position-in-teva-pharmaceutica-a7038f110b34b6acPharma Surgeen2026-07-23T10:25:21.000ZMilitia Capital Management LLC Takes $3.50 Million Position in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-earnings-beat-by-0-29-revenue-topped-estimates-d0bdb0851e3a4703Pharma Surgeen2026-07-23T10:17:35.000ZWest Pharmaceutical Services earnings beat by $0.29, revenue topped estimateshttps://www.pharmaradar360.com/article/environmental-monitoring-following-the-grenfell-tower-fire-85d5cc3f2b36adbcPharma Surgeen2026-07-23T10:16:54.000ZEnvironmental monitoring following the Grenfell Tower firehttps://www.pharmaradar360.com/article/us-intensifies-pressure-on-germany-over-pharmaceutical-pricing-policies-381575514ba09a21Pharma Surgeen2026-07-23T10:16:38.000ZUS intensifies pressure on Germany over pharmaceutical pricing policieshttps://www.pharmaradar360.com/article/west-pharmaceutical-q2-sales-beats-on-biologics-hpv-growth-raises-outlook-8a52b56471dfa5edPharma Surgeen2026-07-23T10:13:03.000ZWest Pharmaceutical Q2 sales beats on biologics, HPV growth; raises outlookhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-earnings-beat-by-0-29-revenue-topped-estimates-f4a8929d8134b097Pharma Surgeen2026-07-23T10:12:00.000ZWest Pharmaceutical Services earnings beat by $0.29, revenue topped estimateshttps://www.pharmaradar360.com/article/west-pharmaceutical-q2-earnings-snapshot-3c5961442b246cddPharma Surgeen2026-07-23T10:07:00.000ZWest Pharmaceutical: Q2 Earnings Snapshothttps://www.pharmaradar360.com/article/class-4-medicines-defect-notification-neuraxpharm-uk-ltd-tuzulby-prolonged-relea-ebc6bd413ec97df1Pharma Surgeen2026-07-23T10:03:27.000ZClass 4 Medicines Defect Notification: Neuraxpharm UK Ltd, Tuzulby prolonged-release chewable tablets, EL(26)A/36https://www.pharmaradar360.com/article/pharmaceutical-company-warns-that-a-single-cigarette-butt-contaminates-a-thousan-1db33d05c6327745Pharma Surgeen2026-07-23T10:01:15.000ZPharmaceutical company warns that a single cigarette butt contaminates a thousand liters of waterhttps://www.pharmaradar360.com/article/brief-west-pharmaceutical-q2-adjusted-eps-usd-2-37-vs-ibes-estimate-usd-2-08-54a264c134d61168Pharma Surgeen2026-07-23T10:01:02.000ZBRIEF-West Pharmaceutical Q2 Adjusted EPS USD 2.37 Vs. IBES Estimate USD 2.08https://www.pharmaradar360.com/article/agricultural-biotech-firm-moa-technology-raises-22-2m-addc719615c4af6fPharma Surgeen2026-07-23T10:00:29.000ZAgricultural biotech firm Moa Technology raises £22.2mhttps://www.pharmaradar360.com/article/la-aemps-habilita-el-procedimiento-para-realizar-la-comunicacion-previa-de-la-fa-5b4cf34ab02ce1fcPharma Surgeen2026-07-23T09:34:28.000ZLa AEMPS habilita el procedimiento para realizar la comunicación previa de la fabricación in house de productos sanitarios para diagnóstico in vitrohttps://www.pharmaradar360.com/article/adult-social-care-client-level-data-england-quarterly-update-to-september-2025-f4f2b3e518324c08Pharma Surgeen2026-07-23T09:30:03.000ZAdult social care client level data, England: quarterly update to September 2025https://www.pharmaradar360.com/article/adult-social-care-client-level-data-england-quarterly-update-to-december-2025-aa0869c7cb4e90dcPharma Surgeen2026-07-23T09:30:03.000ZAdult social care client level data, England: quarterly update to December 2025https://www.pharmaradar360.com/article/adult-social-care-client-level-data-england-quarterly-update-1b4c313e4093d4bbPharma Surgeen2026-07-23T09:30:03.000ZAdult social care client level data, England: quarterly updatehttps://www.pharmaradar360.com/article/cheiron-lands-8-million-seed-for-ai-driven-development-platform-ca273dbfd6973ac6Pharma Surgeen2026-07-23T09:28:10.000ZCheiron lands $8 million seed for AI-driven development platformhttps://www.pharmaradar360.com/article/etcamah-clears-europe-with-us-verdict-on-breast-cancer-switch-pending-41b5b4b16f17d8b3Pharma Surgeen2026-07-23T09:26:38.000ZEtcamah clears Europe with US verdict on breast cancer switch pendinghttps://www.pharmaradar360.com/article/pharmaceutical-technology-90cb93202db361cbPharma Surgeen2026-07-23T09:17:52.000ZPharmaceutical Technologyhttps://www.pharmaradar360.com/article/toni-daa-dhaba-11-others-face-fda-action-over-hygiene-lapses-2d21253e730ce0d3Pharma Surgeen2026-07-23T09:13:14.000ZToni Daa Dhaba, 11 others face FDA action over hygiene lapseshttps://www.pharmaradar360.com/article/a-peptide-showdown-f-d-a-scientists-may-clash-with-r-f-k-s-agenda-465349f9db30bebaPharma Surgeen2026-07-23T09:04:26.000ZA Peptide Showdown: F.D.A. Scientists May Clash With R.F.K.’s Agendahttps://www.pharmaradar360.com/article/fda-panel-considers-easing-peptide-restrictions-6577502417ad171dPharma Surgeen2026-07-23T09:00:00.000ZFDA panel considers easing peptide restrictionshttps://www.pharmaradar360.com/article/dhsc-counter-fraud-strategy-2026-to-2029-bf32b1a2df0da88fPharma Surgeen2026-07-23T08:50:05.000ZDHSC counter-fraud strategy: 2026 to 2029https://www.pharmaradar360.com/article/measles-epidemiology-2023-to-2026-1387e9c40489bd37Pharma Surgeen2026-07-23T08:30:05.000ZMeasles epidemiology 2023 to 2026https://www.pharmaradar360.com/article/shiga-toxin-producing-escherichia-coli-stec-annual-totals-79e6aae9d6d8d0b8Pharma Surgeen2026-07-23T08:30:04.000ZShiga toxin-producing Escherichia coli (STEC): annual totalshttps://www.pharmaradar360.com/article/join-asca2026-in-malaysia-c85b65ec9adf96cdPharma Surgeen2026-07-23T08:29:50.000ZJoin ASCA2026 in Malaysiahttps://www.pharmaradar360.com/article/strong-sales-of-vyvgart-push-results-of-biotech-company-argenx-83fc7cb51313305ePharma Surgeen2026-07-23T08:27:30.000ZStrong sales of Vyvgart push results of biotech company Argenxhttps://www.pharmaradar360.com/article/burning-rock-biotech-limited-sponsored-adr-bnr-shares-sold-by-crcm-lp-299638a0177bd605Pharma Surgeen2026-07-23T08:26:42.000ZBurning Rock Biotech Limited Sponsored ADR $BNR Shares Sold by Crcm LPhttps://www.pharmaradar360.com/article/la-aemps-participa-en-el-proyecto-vac-med-para-fortalecer-las-capacidades-regula-1b405d7678a50d50Pharma Surgeen2026-07-23T08:20:20.000ZLa AEMPS participa en el proyecto Vac-Med para fortalecer las capacidades regulatorias de América Latina y Caribehttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-jiangsu-lianhuan-pharmaceutical-co-ltd-cla-e1b4c77197015c60Pharma Surgeen2026-07-23T08:08:59.000ZEnterprise value to EBITDA forward of Jiangsu Lianhuan Pharmaceutical Co., Ltd. Class A – SSE:600513https://www.pharmaradar360.com/article/uk-and-switzerland-collaborate-to-shape-the-future-of-space-enabled-pharmaceutic-689cebd047fa3a98Pharma Surgeen2026-07-23T08:00:00.000ZUK and Switzerland collaborate to shape the future of space-enabled pharmaceuticalshttps://www.pharmaradar360.com/article/io-biotech-founder-brings-key-lessons-to-new-top-job-i-can-get-through-a-crisis-a2298942c0d1b0ebPharma Surgeen2026-07-23T07:51:00.000ZIO Biotech founder brings key lessons to new top job: “I can get through a crisis”https://www.pharmaradar360.com/article/missed-ai-memory-bull-run-biotech-may-be-the-next-breakout-trade-but-retail-sent-863d61fdca8deb59Pharma Surgeen2026-07-23T07:46:29.000ZMissed AI, Memory Bull Run? Biotech May Be The Next Breakout Trade — But Retail Sentiment Has Never Been Lowerhttps://www.pharmaradar360.com/article/interview-how-tragedy-changed-the-fda-d30cb80e75f0b47aPharma Surgeen2026-07-23T07:44:42.000ZInterview: How Tragedy Changed the FDAhttps://www.pharmaradar360.com/article/ai-biotech-startup-cheiron-launches-8-million-seed-round-430a553d6e4c9d71Pharma Surgeen2026-07-23T07:02:52.000ZAI biotech startup Cheiron launches $8 million seed roundhttps://www.pharmaradar360.com/article/arthex-biotech-publishes-first-demonstration-of-improvement-in-a-dm1-related-beh-58a9d0db863a4b97Pharma Surgeen2026-07-23T07:00:00.000ZARTHEx Biotech Publishes First Demonstration of Improvement in a DM1-related Behavioral Alteration in a Preclinical Model of Myotonic Dystrophy Type 1 (DM1)https://www.pharmaradar360.com/article/jamjoom-pharma-updates-on-non-binding-term-sheet-with-pharmaceutical-investment-917d566624c65d24Pharma Surgeen2026-07-23T06:52:00.000ZJamjoom Pharma Updates On Non-Binding Term Sheet With Pharmaceutical Investment Companyhttps://www.pharmaradar360.com/article/cash-flow-from-investing-activities-of-teh-seng-pharmaceutical-mfg-co-ltd-tpex-7-be404f7d36617888Pharma Surgeen2026-07-23T06:27:44.000ZCash flow from investing activities of Teh Seng Pharmaceutical Mfg Co Ltd – TPEX:7860https://www.pharmaradar360.com/article/bmc-hq-canteen-sealed-by-fda-over-food-safety-lapses-dead-fly-plastic-thread-fou-056b5df98064812dPharma Surgeen2026-07-23T06:12:51.000ZBMC HQ canteen sealed by FDA over food safety lapses; dead fly, plastic thread found in foodhttps://www.pharmaradar360.com/article/world-melting-point-meter-market-analysis-forecast-size-trends-and-insights-c70e375cf8dcaa24Pharma Surgeen2026-07-23T05:56:13.000ZWorld Melting Point Meter - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/kolon-tissuegene-hits-daily-loss-limit-for-third-straight-session-after-u-s-phas-665c9f460472005bPharma Surgeen2026-07-23T05:55:59.000ZKolon TissueGene Hits Daily Loss Limit for Third Straight Session After U.S. Phase 3 Failurehttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-sinopep-allsino-bio-pharmaceutical-co-ltd-0c902ff85f3e230fPharma Surgeen2026-07-23T05:49:31.000ZEnterprise value to EBITDA forward of Sinopep-Allsino Bio Pharmaceutical Co., Ltd. Class A – SSE:688076https://www.pharmaradar360.com/article/phase-3-trial-of-zydus-desidustat-begins-with-hope-for-sickle-cell-patients-301f009626200ac6Pharma Surgeen2026-07-23T05:48:36.000ZPhase 3 trial of Zydus' Desidustat begins with hope for sickle cell patientshttps://www.pharmaradar360.com/article/opinion-trump-s-generic-drug-tariffs-will-drive-up-pharmaceutical-prices-9e17120513f83a99Pharma Surgeen2026-07-23T05:29:35.000ZOpinion | Trump’s generic drug tariffs will drive up pharmaceutical priceshttps://www.pharmaradar360.com/article/zydus-lifesciences-gets-green-light-for-phase-iii-desidustat-trial-in-sickle-cel-dff20607dbfa10acPharma Surgeen2026-07-23T05:02:20.000ZZydus Lifesciences Gets Green Light For Phase III Desidustat Trial In Sickle Cell Patientshttps://www.pharmaradar360.com/article/sartorius-stedim-biotech-continues-positive-development-and-expands-profitable-g-c3a2fafba66805aaPharma Surgeen2026-07-23T05:02:05.000ZSartorius Stedim Biotech continues positive development and expands profitable growthhttps://www.pharmaradar360.com/article/ad-hoc-announcement-pursuant-to-art-53-lr-roche-s-strong-momentum-continues-in-t-1d467bfa5526285cPharma Surgeen2026-07-23T05:00:00.000Z[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franchttps://www.pharmaradar360.com/article/innate-pharma-to-participate-in-a-bladder-cancer-panel-at-the-btig-virtual-biote-a604f44a57062f31Pharma Surgeen2026-07-23T05:00:00.000ZInnate Pharma to participate in a bladder cancer panel at the BTIG Virtual Biotechnology Conferencehttps://www.pharmaradar360.com/article/2026-de8df641c0d48b6cPharma Surgeen2026-07-23T05:00:00.000Zエフ・ホフマン・ラ・ロシュの2026年中間決算発表についてhttps://www.pharmaradar360.com/article/f-hoffmann-la-roche-announces-half-year-results-2026-21af9e371ac6b451Pharma Surgeen2026-07-23T05:00:00.000ZF. Hoffmann-La Roche Announces Half Year Results 2026https://www.pharmaradar360.com/article/is-a-single-patient-kb801-outcome-quietly-reframing-krystal-biotech-s-clinical-n-9187b800db1c8efaPharma Surgeen2026-07-23T04:59:13.000ZIs A Single-Patient KB801 Outcome Quietly Reframing Krystal Biotech's Clinical Narrative (KRYS)?https://www.pharmaradar360.com/article/chinese-ambassador-to-zimbabwe-zhou-ding-visits-china-aided-zimbabwe-national-ph-a8096521792b7eefPharma Surgeen2026-07-23T04:55:00.000ZChinese Ambassador to Zimbabwe Zhou Ding Visits China-aided Zimbabwe National Pharmaceutical Warehousehttps://www.pharmaradar360.com/article/fda-reviews-peptide-injections-favored-by-rfk-jr-and-wellness-influencers-9604737788e22287Pharma Surgeen2026-07-23T04:51:05.000ZFDA reviews peptide injections favored by RFK Jr. and wellness influencershttps://www.pharmaradar360.com/article/how-venture-capital-can-unlock-biotech-s-long-term-value-42ea3ab2aaaa857fPharma Surgeen2026-07-23T04:48:28.000ZHow venture capital can unlock biotech’s long-term valuehttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-tonghua-dongbao-pharmaceutical-co-ltd-class-a-sse-6-656b01c9b1388bc4Pharma Surgeen2026-07-23T04:42:26.000ZPrice to earnings forward of Tonghua Dongbao Pharmaceutical Co., Ltd. Class A – SSE:600867https://www.pharmaradar360.com/article/fda-reviews-controversial-peptide-injections-backed-by-wellness-influencers-9ca2364be4f0381ePharma Surgeen2026-07-23T04:36:27.000ZFDA Reviews Controversial Peptide Injections Backed by Wellness Influencershttps://www.pharmaradar360.com/article/announcement-of-price-revisions-for-specified-products-4b98db19f4cd4507Pharma Surgeen2026-07-23T04:00:00.000ZAnnouncement of Price Revisions for Specified Productshttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-jiangsu-lianhuan-pharmaceutical-co-ltd-class-a-sse-0032aef7dec1f811Pharma Surgeen2026-07-23T03:23:58.000ZPrice to earnings forward of Jiangsu Lianhuan Pharmaceutical Co., Ltd. Class A – SSE:600513https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-hangzhou-biotest-biotech-co-ltd-class-a-sse-a54a700804044cadPharma Surgeen2026-07-23T02:59:52.000ZEnterprise value to EBIT forward of Hangzhou Biotest Biotech Co., Ltd. Class A – SSE:688767https://www.pharmaradar360.com/article/rise-of-ai-and-biotech-reshaping-healthcare-sector-29e436ba9e028cd6Pharma Surgeen2026-07-23T02:57:18.000ZRise of AI and Biotech Reshaping Healthcare Sectorhttps://www.pharmaradar360.com/article/japan-to-mandate-reporting-on-supplement-linked-health-issues-94fc5d046b3ab12bPharma Surgeen2026-07-23T02:31:00.000ZJapan to mandate reporting on supplement-linked health issueshttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-hangzhou-biotest-biotech-co-ltd-class-a-s-44c7d6237a92b068Pharma Surgeen2026-07-23T02:28:48.000ZEnterprise value to revenue forward of Hangzhou Biotest Biotech Co., Ltd. Class A – SSE:688767https://www.pharmaradar360.com/article/popular-allergy-medication-recalled-due-to-potentially-life-threatening-cross-co-ac44ae73bdc61c37Pharma Surgeen2026-07-23T02:19:00.000ZPopular allergy medication recalled due to potentially life-threatening cross contaminationhttps://www.pharmaradar360.com/article/how-new-marine-uas-orders-and-space-biotech-bets-at-redwire-rdw-have-changed-its-e8f0fd31ea98d506Pharma Surgeen2026-07-23T01:38:55.000ZHow New Marine UAS Orders And Space Biotech Bets At Redwire (RDW) Have Changed Its Investment Storyhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-honz-pharmaceutical-co-ltd-class-a-szse-3-f210738aec75a836Pharma Surgeen2026-07-23T01:32:04.000ZEnterprise value to revenue forward of Honz Pharmaceutical Co., Ltd. Class A – SZSE:300086https://www.pharmaradar360.com/article/price-to-earnings-forward-of-hangzhou-biotest-biotech-co-ltd-class-a-sse-688767-e0855f380d2714aePharma Surgeen2026-07-23T01:27:29.000ZPrice to earnings forward of Hangzhou Biotest Biotech Co., Ltd. Class A – SSE:688767https://www.pharmaradar360.com/article/bavaria-emerges-as-global-biotech-hub-with-strong-ecosystem-600058f566a63477Pharma Surgeen2026-07-23T00:53:53.000ZBavaria emerges as global biotech hub with strong ecosystemhttps://www.pharmaradar360.com/article/reporter-s-notebook-there-is-no-partial-success-in-clinical-trials-552109c9b718580aPharma Surgeen2026-07-23T00:50:30.000Z[Reporter’s Notebook] There Is No “Partial Success” in Clinical Trialshttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-zhejiang-huakang-pharmaceutical-co-ltd-class-cb402e14d82ab902Pharma Surgeen2026-07-23T00:34:37.000ZEnterprise value to EBIT forward of Zhejiang Huakang Pharmaceutical Co., Ltd. Class A – SSE:605077https://www.pharmaradar360.com/article/07-22-2026-biotech-in-the-balance-a-conversation-with-author-jeremy-m-levin-m-d-926c4ba1e6051e92Pharma Surgeen2026-07-23T00:23:20.000Z07/22/2026 - BIOTECH IN THE BALANCE - A Conversation with author Jeremy M. Levin, M.D.https://www.pharmaradar360.com/article/kolon-tissuegene-sinks-in-korea-after-us-phase-3-arthritis-drug-misses-goals-cho-bcfd7eb93e6060bdPharma Surgeen2026-07-23T00:19:00.000ZKolon TissueGene sinks in Korea after US phase 3 arthritis drug misses goals - CHOSUNBIZhttps://www.pharmaradar360.com/article/aug-11-from-bench-to-boardroom-women-driving-innovation-across-biotech-e6057188bcba5f45Pharma Surgeen2026-07-23T00:17:30.000ZAug. 11: ‘From Bench to Boardroom: Women Driving Innovation Across Biotech’https://www.pharmaradar360.com/article/is-collegium-pharmaceutical-inc-coll-a-bargain-after-3-1-drop-gf-value-says-unde-1da65c5ec4c52499Pharma Surgeen2026-07-23T00:00:58.000ZIs Collegium Pharmaceutical Inc (COLL) a Bargain After 3.1% Drop? GF Value Says Undervaluedhttps://www.pharmaradar360.com/article/seven-strategies-to-prevent-drowning-technical-package-for-policy-makers-076666d320582265Pharma Surgeen2026-07-23T00:00:00.000ZSeven strategies to prevent drowning: technical package for policy-makershttps://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-28a2b6397d392836Pharma Surgeen2026-07-23T00:00:00.000ZAstraZeneca filed Form 6-Khttps://www.pharmaradar360.com/article/the-device-that-raised-the-alarm-and-saved-my-life-973edc5fa9b945daPharma Surgeen2026-07-23T00:00:00.000ZThe device that raised the alarm and saved my lifehttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-d70758774def05d8Pharma Surgeen2026-07-23T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-aa51134c1fd7241fPharma Surgeen2026-07-23T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-f7c01ed7a31ff392Pharma Surgeen2026-07-23T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-9403ca9ea1ead62dPharma Surgeen2026-07-23T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-5cb1debabb4f6bddPharma Surgeen2026-07-23T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-45fe99b6e78b6347Pharma Surgeen2026-07-23T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-a18aac1ea1186312Pharma Surgeen2026-07-23T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-f4a5215a4bde46f5Pharma Surgeen2026-07-23T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-1439f9335825ba3dPharma Surgeen2026-07-23T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-79602d494a3bd384Pharma Surgeen2026-07-23T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-e0bf3e901f5a7f27Pharma Surgeen2026-07-23T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-837d61492f79d594Pharma Surgeen2026-07-23T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-a8b1ab3250563ba8Pharma Surgeen2026-07-23T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-689af17aefa9d2a2Pharma Surgeen2026-07-23T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/10-july-2026recall-of-remethan-100-r-tablet-100-mgaudienceshealthcare-profession-edf439f1be3a0707Pharma Surgeen2026-07-23T00:00:00.000Z10 July 2026Recall of Remethan 100 R Tablet 100 mgAudiencesHealthcare professionalProduct typeTherapeutic ProductsRetail-level recall of one batch of Remethan 100 R Tablet 100 mg due to out-of-specification results in stability batchesProduct Recallshttps://www.pharmaradar360.com/article/14-july-2026recall-of-decondine-syrupaudienceshealthcare-professionalproduct-typ-400750b28bfa6104Pharma Surgeen2026-07-23T00:00:00.000Z14 July 2026Recall of Decondine SyrupAudiencesHealthcare professionalProduct typeTherapeutic ProductsRetail-level recall of all batches of Decondine Syrup, containing pseudoephedrine and triprolidine, within expiry due to out-of-specification results for triprolidine assay, pH and viscosityProduct Recallshttps://www.pharmaradar360.com/article/17-july-2026recall-of-bd-chlorapreptm-1-ml-applicator-clear-17-july-2026-audienc-e221ec9b9f3fc2efPharma Surgeen2026-07-23T00:00:00.000Z17 July 2026Recall of BD ChloraPrep™ 1 mL Applicator – Clear (17 July 2026)AudiencesHealthcare professionalProduct typeTherapeutic ProductsRetail-level recall of seven batches of BD ChloraPrep™ 1 mL Applicator – Clear due to potential breach of sterility in the packaging.Product Recallshttps://www.pharmaradar360.com/article/15-july-2026how-health-supplements-are-regulated-by-hsaproduct-typehealth-supple-f7c99f7601a253f7Pharma Surgeen2026-07-23T00:00:00.000Z15 July 2026How health supplements are regulated by HSAProduct typeHealth supplementsConsumer Safety Articleshttps://www.pharmaradar360.com/article/15-july-2026getting-savvy-with-health-supplementsproduct-typehealth-supplementsc-a9a82d051c69488cPharma Surgeen2026-07-23T00:00:00.000Z15 July 2026Getting savvy with health supplementsProduct typeHealth supplementsConsumer Safety Articleshttps://www.pharmaradar360.com/article/23-july-20263-consumers-including-a-12-year-old-experienced-serious-adverse-effe-22929ab5fa8f0e7fPharma Surgeen2026-07-23T00:00:00.000Z23 July 20263 Consumers, Including a 12-Year-Old, Experienced Serious Adverse Effects After Taking Products with Banned or Potent Medicinal IngredientsAudiencesConsumerHealthcare professionalIndustry memberProduct typeChinese Proprietary MedicinesHealth supplementsPress Releaseshttps://www.pharmaradar360.com/article/view-latest-results-ec5f7049f7dae5acPharma Surgeen2026-07-23T00:00:00.000ZView latest resultshttps://www.pharmaradar360.com/article/7-23-2026press-releasegalderma-reports-record-first-half-2026-net-sales-of-3-134-858449b248060826Pharma Surgeen2026-07-23T00:00:00.000Z7 . 23 . 2026Press releaseGalderma reports record first half 2026 net sales of 3.134 billion USD and 24.6% year-on-year growth at constant currency, raises net sales guidance for the full yearhttps://www.pharmaradar360.com/article/notice-of-public-data-asset-release-under-the-open-public-electronic-and-necessa-9cadf3c9a1083feePharma Surgeen2026-07-23T00:00:00.000ZNotice of Public Data Asset Release Under the Open, Public, Electronic, and Necessary (OPEN) Government Data Acthttps://www.pharmaradar360.com/article/availability-of-draft-toxicological-profile-for-xylene-extension-of-comment-peri-6519b133ed641f7ePharma Surgeen2026-07-23T00:00:00.000ZAvailability of Draft Toxicological Profile for Xylene; Extension of Comment Periodhttps://www.pharmaradar360.com/article/bulk-manufacturer-of-controlled-substances-application-american-radiolabeled-che-a3aa91a887404b71Pharma Surgeen2026-07-23T00:00:00.000ZBulk Manufacturer of Controlled Substances Application: American Radiolabeled Chemhttps://www.pharmaradar360.com/article/revocation-of-the-color-additive-listing-for-use-of-orange-b-on-casings-or-surfa-9a0a2a0d8520bcdaPharma Surgeen2026-07-23T00:00:00.000ZRevocation of the Color Additive Listing for Use of Orange B on Casings or Surfaces of Frankfurters and Sausageshttps://www.pharmaradar360.com/article/proposal-to-revoke-the-color-additive-listing-for-use-of-citrus-red-no-2-on-the-bf78d1f26dff901dPharma Surgeen2026-07-23T00:00:00.000ZProposal To Revoke the Color Additive Listing for Use of Citrus Red No. 2 on the Skins of Mature Orangeshttps://www.pharmaradar360.com/article/advisory-council-on-alzheimer-s-research-care-and-services-meeting-de56db7305c66a77Pharma Surgeen2026-07-23T00:00:00.000ZAdvisory Council on Alzheimer's Research, Care, and Services; Meetinghttps://www.pharmaradar360.com/article/fda-s-strategy-document-on-facilitating-chemistry-manufacturing-and-controls-rea-7af9b99119a8b9b4Pharma Surgeen2026-07-23T00:00:00.000ZFDA's Strategy Document on Facilitating Chemistry, Manufacturing, and Controls Readiness for Products With Accelerated Clinical Developmenthttps://www.pharmaradar360.com/article/medicaid-program-amending-the-indirect-hold-harmless-threshold-of-health-care-re-39e3c8f7eb6f512cPharma Surgeen2026-07-23T00:00:00.000ZMedicaid Program; Amending the Indirect Hold Harmless Threshold of Health Care-Related Taxeshttps://www.pharmaradar360.com/article/rescinding-guidelines-for-eliminating-discrimination-and-denial-of-services-on-t-3637f1656cab6016Pharma Surgeen2026-07-23T00:00:00.000ZRescinding Guidelines for Eliminating Discrimination and Denial of Services on the Basis of Race, Color, National Origin, Sex, and Handicap in Vocational Education Programshttps://www.pharmaradar360.com/article/prospective-grant-of-an-exclusive-patent-license-rxfp1-agonists-84ef1251e668e7f8Pharma Surgeen2026-07-23T00:00:00.000ZProspective Grant of an Exclusive Patent License: RXFP1 AGONISTShttps://www.pharmaradar360.com/article/advisory-committee-peripheral-and-central-nervous-system-drugs-advisory-committe-3a570c5474440820Pharma Surgeen2026-07-23T00:00:00.000ZAdvisory Committee; Peripheral and Central Nervous System Drugs Advisory Committee; Termination and Reestablishmenthttps://www.pharmaradar360.com/article/etcamah-camizestrant-in-combination-with-a-cdk4-6-inhibitor-approved-in-the-eu-f-da394426e6107cadPharma Surgeen2026-07-23T00:00:00.000ZEtcamah (camizestrant) in combination with a CDK4/6 inhibitor approved in the EU for 1st-line advanced ER-positive breast cancerhttps://www.pharmaradar360.com/article/wave-life-sciences-second-quarter-2026-financial-results-scheduled-for-july-30-2-521758f1b62b0ad4Pharma Surgeen2026-07-23T00:00:00.000ZWave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026https://www.pharmaradar360.com/article/united-therapeutics-corporation-announces-appointment-of-victor-dzau-to-its-boar-d366321c2ab459aaPharma Surgeen2026-07-23T00:00:00.000ZUnited Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directorshttps://www.pharmaradar360.com/article/drug-drug-interaction-signals-for-sexual-dysfunction-with-antidepressants-and-an-ab630fead060bdf6Pharma Surgeen2026-07-23T00:00:00.000ZDrug-Drug Interaction Signals for Sexual Dysfunction with Antidepressants and Antipsychotics: A Pharmacovigilance-Pharmacodynamic Studyhttps://www.pharmaradar360.com/article/clinical-radiological-and-surgical-insights-into-sciatic-schwannoma-a-rare-perip-a9b1ffdfa532413bPharma Surgeen2026-07-23T00:00:00.000ZClinical, Radiological, and Surgical Insights into Sciatic Schwannoma: A Rare Peripheral Nerve Tumourhttps://www.pharmaradar360.com/article/congenital-heart-diseases-in-children-a-narrative-analysis-of-early-diagnosis-cl-4b6339695fbbd1f9Pharma Surgeen2026-07-23T00:00:00.000ZCongenital Heart Diseases in Children: A Narrative Analysis of Early Diagnosis, Clinical Management, and Long-Term Outcomeshttps://www.pharmaradar360.com/article/device-associated-infections-caused-by-lt-i-gt-escherichia-coli-lt-i-gt-in-hospi-7373879c99d84a07Pharma Surgeen2026-07-23T00:00:00.000ZDevice-Associated Infections Caused by &lt;i&gt;Escherichia coli&lt;/i&gt; in Hospitalized Patients: Mechanisms and Clinical Impacthttps://www.pharmaradar360.com/article/clinical-and-molecular-characterization-of-rare-inherited-metabolic-disorders-in-d4836019df387c70Pharma Surgeen2026-07-23T00:00:00.000ZClinical and Molecular Characterization of Rare Inherited Metabolic Disorders in a Tertiary Care Genetics Clinichttps://www.pharmaradar360.com/article/endocrine-disrupting-chemicals-in-cosmetics-mechanisms-health-impacts-and-pharma-7a4a911624122706Pharma Surgeen2026-07-23T00:00:00.000ZEndocrine-Disrupting Chemicals in Cosmetics: Mechanisms, Health Impacts, and Pharmaceutical Approaches for Safer Formulationshttps://www.pharmaradar360.com/article/clinical-characteristics-prompt-diagnosis-and-in-hospital-treatment-outcomes-of-ea4a867d9a039878Pharma Surgeen2026-07-23T00:00:00.000ZClinical characteristics, prompt diagnosis, and in-hospital treatment outcomes of acute renal artery occlusion at Cardiovascular Center – E Hospitalhttps://www.pharmaradar360.com/article/evaluation-of-drug-interactions-in-preclinical-theranostic-imaging-800d4e5ae3fd7f78Pharma Surgeen2026-07-23T00:00:00.000ZEvaluation of Drug Interactions in Preclinical Theranostic Imaginghttps://www.pharmaradar360.com/article/the-effects-of-plyometric-training-on-selected-neuromuscular-outcomes-in-trained-87d2548e7ee072adPharma Surgeen2026-07-23T00:00:00.000ZThe Effects of Plyometric Training on Selected Neuromuscular Outcomes in Trained-to-Highly Trained Male Boulder Climbers: A Preliminary Exploratory Trialhttps://www.pharmaradar360.com/article/electrohysterography-for-uterine-contractility-monitoring-measurement-principles-03a4d161d2813da0Pharma Surgeen2026-07-23T00:00:00.000ZElectrohysterography for Uterine Contractility Monitoring: Measurement Principles, Clinical Evidence, and Reporting Recommendationshttps://www.pharmaradar360.com/article/structural-and-computationally-driven-molecule-design-in-drug-discovery-current-fe605df73e47d965Pharma Surgeen2026-07-23T00:00:00.000ZStructural and Computationally Driven Molecule Design in Drug Discovery: Current Advances and Future Perspectiveshttps://www.pharmaradar360.com/article/hyperkalemia-risk-after-finerenone-initiation-in-diabetic-kidney-disease-with-el-4dd64dc9aa07c36cPharma Surgeen2026-07-23T00:00:00.000ZHyperkalemia Risk After Finerenone Initiation in Diabetic Kidney Disease with Elevated Baseline Potassium: A Multicenter Cohort Studyhttps://www.pharmaradar360.com/article/results-of-endovascular-treatment-of-ruptured-intracranial-aneurysms-and-recanal-283754e3768a125bPharma Surgeen2026-07-23T00:00:00.000ZResults of Endovascular Treatment of Ruptured Intracranial Aneurysms and Recanalization Rate After a Five-Year Follow-Up Periodhttps://www.pharmaradar360.com/article/the-feasibility-of-one-stage-instance-segmentation-for-detecting-oral-potentiall-4bab2e2f4e81afbePharma Surgeen2026-07-23T00:00:00.000ZThe Feasibility of One-Stage Instance Segmentation for Detecting Oral Potentially Malignant Disorders in White-Light Clinical Photographs: A Proof-of-Concept Studyhttps://www.pharmaradar360.com/article/ultrasound-elastography-in-chronic-liver-disease-from-clinical-applications-to-q-8c73e957da18f69fPharma Surgeen2026-07-23T00:00:00.000ZUltrasound Elastography in Chronic Liver Disease: From Clinical Applications to Quality Assurance and Future Perspectiveshttps://www.pharmaradar360.com/article/clinical-diagnosis-and-treatment-in-patients-with-schwannoma-at-a-single-institu-9dcb9035e16e6748Pharma Surgeen2026-07-23T00:00:00.000ZClinical Diagnosis and Treatment in Patients with Schwannoma at a Single Institutehttps://www.pharmaradar360.com/article/clinical-outcomes-and-healthcare-resource-utilization-results-among-hospitalized-2130d8e7252bbd81Pharma Surgeen2026-07-23T00:00:00.000ZClinical Outcomes and Healthcare Resource Utilization Results Among Hospitalized Adults with Cystic Fibrosis Treated with Ceftolozane/Tazobactam: A SPECTRA Real-World Subgroup Analysishttps://www.pharmaradar360.com/article/pesticide-specific-case-fatality-and-clinical-outcomes-among-poisoning-cases-in-23217414e75078b0Pharma Surgeen2026-07-23T00:00:00.000ZPesticide-specific case fatality and clinical outcomes among poisoning cases in Tanzania: a retrospective cross-sectional studyhttps://www.pharmaradar360.com/article/from-observation-to-evidence-harnessing-the-mental-status-examination-as-a-real-08affecd6bbb4d25Pharma Surgeen2026-07-23T00:00:00.000ZFrom observation to evidence: harnessing the mental status examination as a real-world data source in clinical researchhttps://www.pharmaradar360.com/article/physical-activity-and-exercise-in-dementia-clinical-relevance-and-emerging-insig-7d25f2f616f5a836Pharma Surgeen2026-07-23T00:00:00.000ZPhysical activity and exercise in dementia: clinical relevance and emerging insightshttps://www.pharmaradar360.com/article/evaluation-of-fourier-transform-infrared-spectroscopy-as-a-first-line-surveillan-6058a9db22f1afbcPharma Surgeen2026-07-23T00:00:00.000ZEvaluation of Fourier transform infrared spectroscopy as a first-line surveillance typing tool for Serratia spp. isolates derived from clinical materialshttps://www.pharmaradar360.com/article/development-and-initial-validation-of-a-modular-life-course-health-education-and-edf849d270eb5bc5Pharma Surgeen2026-07-23T00:00:00.000ZDevelopment and initial validation of a modular life-course health education and science communication needs scale for Chinese clinical and community service users: a Tianjin-based studyhttps://www.pharmaradar360.com/article/electroencephalography-for-early-alzheimer-s-disease-diagnosis-from-advanced-fea-a30678e69b76b77dPharma Surgeen2026-07-23T00:00:00.000ZElectroencephalography for early Alzheimer’s disease diagnosis: from advanced feature engineering to interpretable ai and clinical translationhttps://www.pharmaradar360.com/article/prediction-of-early-treatment-response-to-drug-eluting-beads-chemoembolization-f-b24500421c5048d4Pharma Surgeen2026-07-23T00:00:00.000ZPrediction of early treatment response to drug-eluting beads chemoembolization for hepatocellular carcinoma using machine learninghttps://www.pharmaradar360.com/article/clinical-characteristics-and-risk-factors-of-acute-cutaneous-graft-vs-host-disea-620ed25d7d027034Pharma Surgeen2026-07-23T00:00:00.000ZClinical characteristics and risk factors of acute cutaneous graft-vs.-host disease following allogeneic hematopoietic stem cell transplantation in pediatric acute myeloid leukemia: a single-center retrospective studyhttps://www.pharmaradar360.com/article/combined-use-of-emla-cream-and-buzzy-for-peripheral-intravenous-cannulation-in-c-323dce35d853ea55Pharma Surgeen2026-07-23T00:00:00.000ZCombined use of EMLA cream and Buzzy for peripheral intravenous cannulation in children: a randomized controlled trialhttps://www.pharmaradar360.com/article/folic-acid-supplementation-and-observed-clinical-outcomes-in-pediatric-primary-m-1713583b2828524aPharma Surgeen2026-07-23T00:00:00.000ZFolic acid supplementation and observed clinical outcomes in pediatric primary monosymptomatic nocturnal enuresis: a prospective single-arm cohort study from Gaza (2023–2025)https://www.pharmaradar360.com/article/neurodynamic-techniques-vs-desensitization-maneuvers-in-the-manual-therapy-manag-78df4920f8b85750Pharma Surgeen2026-07-23T00:00:00.000ZNeurodynamic techniques vs. desensitization maneuvers in the manual therapy management of moderate carpal tunnel syndrome among women: randomized clinical trial with 1-year follow-uphttps://www.pharmaradar360.com/article/surgical-management-of-sickle-cell-retinopathy-a-systematic-review-of-clinical-o-a1cfbe0b49f5ff5aPharma Surgeen2026-07-23T00:00:00.000ZSurgical management of sickle cell retinopathy: a systematic review of clinical outcomes and a single-arm meta-analysis of single-surgery anatomical successhttps://www.pharmaradar360.com/article/vulvar-malignant-melanoma-versus-vaginal-malignant-melanoma-distinct-biology-dis-b9f667def34ff14aPharma Surgeen2026-07-23T00:00:00.000ZVulvar malignant melanoma versus vaginal malignant melanoma: distinct biology, distinct clinical behavior, and distinct management?https://www.pharmaradar360.com/article/predictive-value-of-sarcopenia-related-clinical-indices-for-early-disease-progre-b1b8adf062dbd2f2Pharma Surgeen2026-07-23T00:00:00.000ZPredictive value of sarcopenia-related clinical indices for early disease progression in acute pancreatitis: a multicenter retrospective cohort studyhttps://www.pharmaradar360.com/article/artificial-intelligence-in-psychiatry-clinical-applications-limitations-and-ethi-cbe7a70fcfe63f14Pharma Surgeen2026-07-23T00:00:00.000ZArtificial intelligence in psychiatry: clinical applications, limitations, and ethical challengeshttps://www.pharmaradar360.com/article/clinical-study-on-the-screening-of-biomarkers-for-crohn-s-disease-based-on-blood-e56fb772a1468253Pharma Surgeen2026-07-23T00:00:00.000ZClinical study on the screening of biomarkers for Crohn’s disease based on blood metabolomicshttps://www.pharmaradar360.com/article/artificial-intelligence-in-hiv-research-a-structured-review-and-task-oriented-cl-50251ef700430539Pharma Surgeen2026-07-23T00:00:00.000ZArtificial intelligence in HIV research: a structured review and task-oriented clinical frameworkhttps://www.pharmaradar360.com/article/advanced-hydrogels-for-tissue-engineering-and-regenerative-medicine-from-materia-3646934859bc9f4ePharma Surgeen2026-07-23T00:00:00.000ZAdvanced hydrogels for tissue engineering and regenerative medicine: from material design to clinical translationhttps://www.pharmaradar360.com/article/the-influence-of-post-resuscitation-debriefing-and-clinical-learning-environment-7419a4fe4efc1cfaPharma Surgeen2026-07-23T00:00:00.000ZThe influence of post-resuscitation debriefing and clinical learning environment on CPR quality and resuscitation self-efficacy among emergency department healthcare workershttps://www.pharmaradar360.com/article/treatment-needs-and-surgical-intervention-outcomes-in-children-with-oral-clefts-4adc57a238693165Pharma Surgeen2026-07-23T00:00:00.000ZTreatment needs and surgical intervention outcomes in children with oral clefts managed in the region of Geita, Tanzania, East Africahttps://www.pharmaradar360.com/article/exploring-the-antioxidant-properties-of-digera-muricata-l-mart-leaves-through-in-6daaf8625611756dPharma Surgeen2026-07-23T00:00:00.000ZExploring the Antioxidant Properties of Digera muricata (L.) Mart. Leaves Through In Vitro Assayshttps://www.pharmaradar360.com/article/hemodynamic-responses-to-pneumoperitoneum-in-laparoscopic-surgery-anaesthetic-im-9fb9f4ff04a7d766Pharma Surgeen2026-07-23T00:00:00.000ZHEMODYNAMIC RESPONSES TO PNEUMOPERITONEUM IN LAPAROSCOPIC SURGERY: ANAESTHETIC IMPLICATIONS AND MANAGEMENT STRATEGIEShttps://www.pharmaradar360.com/article/genetic-analysis-of-the-ctla-4-ct60-a-g-polymorphism-in-vitiligo-a-pilot-study-i-1f678bdf3555a0bcPharma Surgeen2026-07-23T00:00:00.000ZGenetic Analysis of the CTLA-4 CT60 A/G Polymorphism in Vitiligo: A Pilot Study in an Egyptian Cohorthttps://www.pharmaradar360.com/article/versatility-of-the-pedicled-anterolateral-thigh-flap-for-reconstruction-after-tu-16133727c5d3af6cPharma Surgeen2026-07-23T00:00:00.000ZVersatility of The Pedicled Anterolateral Thigh Flap for Reconstruction After Tumor Resectionhttps://www.pharmaradar360.com/article/investigation-of-thermal-and-dynamic-mechanical-behaviour-of-stir-cast-al5083-hy-342d3c8759738829Pharma Surgeen2026-07-23T00:00:00.000ZInvestigation of Thermal and Dynamic Mechanical Behaviour of Stir-Cast Al5083 Hybrid Composites Reinforced with Nano-ZrO2 and Nano-SiChttps://www.pharmaradar360.com/article/a-low-power-14t-sram-using-self-resilience-radiationhardened-technique-for-aeros-3de8c0bb1201ce1bPharma Surgeen2026-07-23T00:00:00.000ZA LOW POWER 14T SRAM USING SELF-RESILIENCE RADIATIONHARDENED TECHNIQUE FOR AEROSPACE APPLICATIONhttps://www.pharmaradar360.com/article/comparative-evaluation-of-retentive-strength-of-orthodontic-bands-cemented-with-0b565b4ace5fc794Pharma Surgeen2026-07-23T00:00:00.000ZComparative Evaluation Of Retentive Strength Of Orthodontic Bands Cemented With Conventional Glass Ionomer Cement, Resin-Modified Glass Ionomer Cement, And Resin Cement: An In-Vitro Studyhttps://www.pharmaradar360.com/article/the-neurologist-as-interpreter-reading-what-is-hidden-in-contemporary-clinical-n-79f361f211d1fc66Pharma Surgeen2026-07-23T00:00:00.000ZThe neurologist as interpreter: reading what is hidden in contemporary clinical neurosciencehttps://www.pharmaradar360.com/article/clinical-variability-in-stiff-person-syndrome-a-systematic-review-of-atypical-pr-0e2db32db3112606Pharma Surgeen2026-07-23T00:00:00.000ZClinical variability in stiff-person syndrome: a systematic review of atypical presentationshttps://www.pharmaradar360.com/article/autonomous-bladder-training-for-neurogenic-bladder-a-randomized-controlled-trial-bd239e786617e919Pharma Surgeen2026-07-23T00:00:00.000ZAutonomous bladder training for neurogenic bladder: a randomized controlled trialhttps://www.pharmaradar360.com/article/ocular-leptospirosis-as-the-sole-clinical-manifestation-in-a-pediatric-patient-a-850f5412c745ca70Pharma Surgeen2026-07-23T00:00:00.000ZOcular leptospirosis as the sole clinical manifestation in a pediatric patient: an atypical casehttps://www.pharmaradar360.com/article/from-clinical-question-to-testable-hypothesis-using-ai-co-scientist-to-identify-6bd62434fe8eb243Pharma Surgeen2026-07-23T00:00:00.000ZFrom Clinical Question to Testable Hypothesis: Using AI Co-Scientist to Identify Repurposable Drugs for Alpha-Gal Syndromehttps://www.pharmaradar360.com/article/is6110-derived-fusion-transcripts-in-clinical-mycobacterium-tuberculosis-genomic-efafc03726dd869fPharma Surgeen2026-07-23T00:00:00.000ZIS6110-derived fusion transcripts in clinical Mycobacterium tuberculosis: Genomic and Transcriptomic evidence for genome plasticityhttps://www.pharmaradar360.com/article/estimating-drinking-water-pfas-exposures-associated-with-serum-clinical-action-l-ddd94eb7c75dce40Pharma Surgeen2026-07-23T00:00:00.000ZEstimating drinking water PFAS exposures associated with serum clinical action levels using a probabilistic toxicokinetic modelhttps://www.pharmaradar360.com/article/lack-of-resolution-of-inflammation-marks-malignant-pleural-mesothelioma-progress-0fede9af129241d9Pharma Surgeen2026-07-23T00:00:00.000ZLack of resolution of inflammation marks malignant pleural mesothelioma progressionhttps://www.pharmaradar360.com/article/two-cases-of-paroxysmal-nocturnal-hemoglobinuria-clinical-observations-and-treat-6cf4aaff33e4cf30Pharma Surgeen2026-07-23T00:00:00.000ZTwo cases of paroxysmal nocturnal hemoglobinuria: Clinical observations and treatment approacheshttps://www.pharmaradar360.com/article/touch-over-technology-landmark-guided-clavipectoral-fascial-plane-block-in-clavi-ec6216f2727cddf3Pharma Surgeen2026-07-23T00:00:00.000ZTouch over technology-landmark-guided clavipectoral fascial plane block in clavicle surgeries: A case serieshttps://www.pharmaradar360.com/article/anaesthetic-management-in-coblation-assisted-posterior-cordectomy-for-chronic-bi-7c140cf1e667c8b8Pharma Surgeen2026-07-23T00:00:00.000ZAnaesthetic management in coblation- Assisted posterior cordectomy for chronic bilateral abductor vocal fold paralysis: A case reporthttps://www.pharmaradar360.com/article/preoperative-gastric-residual-volumes-in-diabetic-versus-non-diabetic-patients-a-eb3d54d88b4e5123Pharma Surgeen2026-07-23T00:00:00.000ZPreoperative gastric residual volumes in diabetic versus non-diabetic patients: A prospective randomized comparative study using point-of-care ultrasound assessmenthttps://www.pharmaradar360.com/article/efficacy-of-ultrasound-guided-versus-surgically-administered-erector-spinae-plan-68829f0a15be7d42Pharma Surgeen2026-07-23T00:00:00.000ZEfficacy of ultrasound-guided versus surgically administered erector spinae plane block with bupivacaine and dexmedetomidine in lumbar spinal fusion surgery: A prospective randomized double-blinded clinical trialhttps://www.pharmaradar360.com/article/acute-normovolemic-hemodilution-for-mitral-valve-replacement-in-a-patient-with-b-6eba9219afe286e8Pharma Surgeen2026-07-23T00:00:00.000ZAcute normovolemic hemodilution for mitral valve replacement in a patient with Bombay blood phenotype: A case reporthttps://www.pharmaradar360.com/article/experience-in-treatment-of-secondary-amyloidosis-and-extensive-non-healing-wound-06aa8e83a2376d30Pharma Surgeen2026-07-23T00:00:00.000ZEXPERIENCE IN TREATMENT OF SECONDARY AMYLOIDOSIS AND EXTENSIVE NON-HEALING WOUNDS IN A PATIENT WITH CONGENITAL EPIDERMOLYSIS BULLOSIShttps://www.pharmaradar360.com/article/sciatic-nerve-anatomical-variations-and-deep-gluteal-syndrome-clinical-relevance-59416bc914c3e85cPharma Surgeen2026-07-23T00:00:00.000ZSciatic Nerve Anatomical Variations and Deep Gluteal Syndrome: Clinical Relevance and Current Evidence — A Narrative Literature Review&lt;b&gt;&lt;/b&gt;https://www.pharmaradar360.com/article/evaluation-of-the-sysmex-uc-1000-test-strip-reader-fit-for-purpose-in-a-point-of-1c67a7b1e96f0b5ePharma Surgeen2026-07-23T00:00:00.000ZEvaluation of the Sysmex UC-1000 test strip reader: fit for purpose in a point-of-care setting?https://www.pharmaradar360.com/article/serum-hcg-reference-values-in-menopausal-women-across-four-immunoassay-platforms-62e1440fe0878ef4Pharma Surgeen2026-07-23T00:00:00.000ZSerum hCG reference values in menopausal women across four immunoassay platforms: implications of renal function for clinical interpretationhttps://www.pharmaradar360.com/article/autologous-peritoneal-patch-for-venous-reconstruction-a-systematic-review-of-cli-5c6209b0a08c20a0Pharma Surgeen2026-07-23T00:00:00.000ZAutologous peritoneal patch for venous reconstruction: A systematic review of clinical outcomeshttps://www.pharmaradar360.com/article/what-s-next-for-prescription-drug-affordability-boards-after-amp-lt-i-amp-gt-amg-4252c0096ace85e1Pharma Surgeen2026-07-23T00:00:00.000ZWhat’s Next For Prescription Drug Affordability Boards After &amp;lt;i&amp;gt;Amgen v. Mizner&amp;lt;/i&amp;gt;?https://www.pharmaradar360.com/article/surface-oxidized-nanoplastics-exhibit-increased-interaction-with-thp-1-cells-a7af6be69c6d19bdPharma Surgeen2026-07-23T00:00:00.000ZSurface-Oxidized Nanoplastics Exhibit Increased Interaction with THP-1 Cellshttps://www.pharmaradar360.com/article/dihydrotanshinone-i-attenuates-atherosclerosis-lt-i-gt-via-lt-i-gt-inhibiting-nl-38f33096ba8d95fdPharma Surgeen2026-07-23T00:00:00.000ZDihydrotanshinone I Attenuates Atherosclerosis &lt;i&gt;via&lt;/i&gt; Inhibiting NLRP3 Inflammasome Activation and Modulating Gut Microbiotahttps://www.pharmaradar360.com/article/do-3d-printed-craniofacial-fracture-models-improve-learning-outcomes-in-maxillof-24c2213420832447Pharma Surgeen2026-07-23T00:00:00.000ZDo 3D-printed craniofacial fracture models improve learning outcomes in maxillofacial trauma? A multicenter cluster-randomized trialhttps://www.pharmaradar360.com/article/radiosynthesis-and-quality-control-testing-of-two-18f-labeled-radiopharmaceutica-f64952477ed9828dPharma Surgeen2026-07-23T00:00:00.000ZRadiosynthesis and quality control testing of two 18F-labeled radiopharmaceuticals for α-synuclein imaging in clinical investigationshttps://www.pharmaradar360.com/article/efficacy-of-a-psychotherapeutic-group-intervention-for-patients-with-post-covid-2814e69c0640084fPharma Surgeen2026-07-23T00:00:00.000ZEfficacy of a psychotherapeutic group intervention for patients with Post-COVID-19 condition: a randomized controlled trial (PsyLoCo study)https://www.pharmaradar360.com/article/fubp1-lactylation-suppresses-trophoblast-function-in-fetal-growth-restriction-e94fee5effc74d39Pharma Surgeen2026-07-23T00:00:00.000ZFUBP1 lactylation suppresses trophoblast function in fetal growth restrictionhttps://www.pharmaradar360.com/article/intracluster-correlation-coefficients-for-neonatal-trials-an-analysis-of-nationa-dcb50efed5343339Pharma Surgeen2026-07-23T00:00:00.000ZIntracluster correlation coefficients for neonatal trials: an analysis of national population level clinical datahttps://www.pharmaradar360.com/article/efficacy-of-a-stepped-care-approach-for-school-age-children-with-mild-to-moderat-42d4a347e4395579Pharma Surgeen2026-07-23T00:00:00.000ZEfficacy of a stepped-care approach for school-age children with mild to moderate ADHD (ESCAschool-moderate): an adaptive intervention study including a randomized controlled trialhttps://www.pharmaradar360.com/article/metabolomic-signatures-of-early-pathway-disruptions-and-clinical-outcomes-in-com-453a577fe49750c9Pharma Surgeen2026-07-23T00:00:00.000ZMetabolomic signatures of early pathway disruptions and clinical outcomes in community-acquired pneumonia: a prospective case-control studyhttps://www.pharmaradar360.com/article/exploring-the-feasibility-safety-and-preliminary-clinical-effects-of-amygdala-ta-8a03a4faba95b6b8Pharma Surgeen2026-07-23T00:00:00.000ZExploring the feasibility, safety and preliminary clinical effects of amygdala-targeted temporal interference stimulation for major depressive disorder: a pilot studyhttps://www.pharmaradar360.com/article/protocol-for-a-parallel-group-superiority-randomized-controlled-trial-comparing-9933aa20ea25f754Pharma Surgeen2026-07-23T00:00:00.000ZProtocol for a parallel-group superiority randomized controlled trial comparing Sage– a couple psychotherapy– to supportive individual psychotherapy for borderline personality disorderhttps://www.pharmaradar360.com/article/retrospective-cross-sectional-study-of-clinical-and-laboratory-profiles-of-paedi-7e663423b443b009Pharma Surgeen2026-07-23T00:00:00.000ZRetrospective cross-sectional study of clinical and laboratory profiles of paediatric tuberculosis at Ayder Comprehensive Specialized Hospital, Ethiopia (2018–2021)https://www.pharmaradar360.com/article/age-related-differences-in-clinical-manifestations-neuroimaging-features-and-tre-f6727af5a23aca03Pharma Surgeen2026-07-23T00:00:00.000ZAge-related differences in clinical manifestations, neuroimaging features, and treatment of spontaneous intracranial hypotension: a retrospective cohort studyhttps://www.pharmaradar360.com/article/the-len4prep-study-protocol-for-a-phase-3b-non-randomised-clinical-trial-integra-49dad33454869a47Pharma Surgeen2026-07-23T00:00:00.000ZThe LEN4PrEP study: protocol for a phase 3B, non-randomised clinical trial integrating lenacapavir PrEP within multi-product HIV prevention services in primary care clinics in South Africahttps://www.pharmaradar360.com/article/effectiveness-of-oral-and-inhaled-repurposed-and-antiviral-pharmaceutical-treatm-8aaca5c21a6c4181Pharma Surgeen2026-07-23T00:00:00.000ZEffectiveness of oral and inhaled repurposed and antiviral pharmaceutical treatments for acute SARS-CoV-2 in outpatient settings: a systematic review of 124 randomized trialshttps://www.pharmaradar360.com/article/implementing-cognitive-training-in-primary-health-care-for-older-adults-with-mci-72782604bf4534cfPharma Surgeen2026-07-23T00:00:00.000ZImplementing cognitive training in primary health care for older adults with MCI: study protocol for a type 3 hybrid effectiveness-implementation cluster-randomized factorial trialhttps://www.pharmaradar360.com/article/reduced-exposure-neuromuscular-blockade-strategies-for-total-laparoscopic-hyster-c8030816f4a4e7f5Pharma Surgeen2026-07-23T00:00:00.000ZReduced-exposure neuromuscular blockade strategies for total laparoscopic hysterectomy within an ERAS pathway: a randomized controlled trialhttps://www.pharmaradar360.com/article/repurposing-amlodipine-fluoxetine-and-escitalopram-as-non-antibiotic-adjuvants-i-a9b3ef9327315634Pharma Surgeen2026-07-23T00:00:00.000ZRepurposing amlodipine, fluoxetine, and escitalopram as non-antibiotic adjuvants: in vitro enhancement of ciprofloxacin and fluconazole activity against multidrug-resistant bacterial and candida clinical isolateshttps://www.pharmaradar360.com/article/effectiveness-of-telerehabilitation-on-upper-limb-functionality-in-women-after-b-1e4d44aac7edd688Pharma Surgeen2026-07-23T00:00:00.000ZEffectiveness of telerehabilitation on upper limb functionality in women after breast cancer treatment: A systematic review of randomized clinical trialshttps://www.pharmaradar360.com/article/curcumin-s-dermatological-potential-from-multifaceted-mechanisms-to-advanced-del-40b0098fdd922950Pharma Surgeen2026-07-23T00:00:00.000ZCurcumin’s Dermatological Potential: From Multifaceted Mechanisms to Advanced Delivery Systems and Clinical Translationhttps://www.pharmaradar360.com/article/rethinking-molecular-profiling-after-first-line-osimertinib-740b9a2b532790d2Pharma Surgeen2026-07-23T00:00:00.000ZRethinking Molecular Profiling after First-line Osimertinibhttps://www.pharmaradar360.com/article/reducing-hyperkalemia-in-hemodialysis-a-nurse-led-quality-improvement-project-us-042eafe957a13563Pharma Surgeen2026-07-23T00:00:00.000ZReducing hyperkalemia in hemodialysis: a nurse-led quality improvement project using the clinical translation modelhttps://www.pharmaradar360.com/article/recommendations-for-assessing-methodological-quality-in-systematic-reviews-of-po-61aa75ef3db5046cPharma Surgeen2026-07-23T00:00:00.000ZRecommendations for Assessing Methodological Quality in Systematic Reviews of Population Pharmacokinetic Models: A Systematic Reviewhttps://www.pharmaradar360.com/article/corr-synthesis-rethinking-value-in-orthopaedic-surgery-why-current-metrics-fall-e148f9a1e1a64c1aPharma Surgeen2026-07-23T00:00:00.000ZCORR Synthesis: Rethinking Value in Orthopaedic Surgery—Why Current Metrics Fall Shorthttps://www.pharmaradar360.com/article/predictors-of-sacroiliac-joint-intervention-following-lumbar-spine-fusion-95b909d153fe0affPharma Surgeen2026-07-23T00:00:00.000ZPredictors of Sacroiliac Joint Intervention Following Lumbar Spine Fusionhttps://www.pharmaradar360.com/article/individual-and-family-level-risk-factors-of-daily-opioid-use-in-adolescents-foll-6deb93fc94123901Pharma Surgeen2026-07-23T00:00:00.000ZIndividual and Family-Level Risk Factors of Daily Opioid Use in Adolescents Following Spinal Fusion Surgeryhttps://www.pharmaradar360.com/article/phase-2-randomized-bivalent-rsvpref-maternal-vaccine-trial-final-safety-antibody-e9cea7e50bb02958Pharma Surgeen2026-07-23T00:00:00.000ZPhase 2 Randomized Bivalent RSVpreF Maternal Vaccine Trial: Final Safety, Antibody Persistence and Efficacyhttps://www.pharmaradar360.com/article/when-certainty-is-lost-navigating-diagnostic-uncertainty-after-specimen-depletio-21f9a096ee1eb819Pharma Surgeen2026-07-23T00:00:00.000ZWhen certainty is lost: Navigating diagnostic uncertainty after specimen depletionhttps://www.pharmaradar360.com/article/cutaneous-leishmaniasis-in-patients-in-treatment-with-anti-tnf-drugs-study-of-20-5e6a8ff845bba922Pharma Surgeen2026-07-23T00:00:00.000ZCutaneous leishmaniasis in patients in treatment with anti-TNF-α drugs. Study of 20 cases from a single institutionhttps://www.pharmaradar360.com/article/latent-variables-in-cognitive-decline-introducing-a-behavioral-relational-factor-c3a97b97009be09fPharma Surgeen2026-07-23T00:00:00.000ZLatent variables in cognitive decline: introducing a behavioral-relational factorhttps://www.pharmaradar360.com/article/soft-contact-lens-wear-in-children-benefits-and-limitations-976da3569fc6a7bePharma Surgeen2026-07-23T00:00:00.000ZSoft contact lens wear in children: benefits and limitationshttps://www.pharmaradar360.com/article/the-best-of-both-worlds-using-clinical-trial-and-observational-data-to-evaluate-db561cdb46705e30Pharma Surgeen2026-07-23T00:00:00.000ZThe Best of Both Worlds — Using Clinical Trial and Observational Data to Evaluate Vaccine Protectionhttps://www.pharmaradar360.com/article/when-celebrities-prescribe-regulating-drug-promotion-on-the-internet-c35a63baabec57abPharma Surgeen2026-07-23T00:00:00.000ZWhen Celebrities Prescribe — Regulating Drug Promotion on the Internethttps://www.pharmaradar360.com/article/clinical-long-read-genome-sequencing-for-rare-disease-diagnostics-092c6bdf24906f5dPharma Surgeen2026-07-23T00:00:00.000ZClinical Long-Read Genome Sequencing for Rare-Disease Diagnosticshttps://www.pharmaradar360.com/article/effects-of-cold-plasma-systems-applied-to-sutures-used-in-third-molar-surgery-on-c993013ed2038f65Pharma Surgeen2026-07-23T00:00:00.000ZEffects of cold plasma systems applied to sutures used in third molar surgery on postoperative sequelae and quality of life: a randomized pilot clinical trialhttps://www.pharmaradar360.com/article/quantum-classical-hybrid-learning-framework-for-parkinson-s-disease-prediction-u-731adcd3a1c5c16aPharma Surgeen2026-07-23T00:00:00.000ZQuantum-classical hybrid learning framework for Parkinson’s disease prediction using acoustic and clinical featureshttps://www.pharmaradar360.com/article/identification-of-key-clinical-features-and-development-of-a-machine-learning-mo-e0f4b7a0ea6f0cc5Pharma Surgeen2026-07-23T00:00:00.000ZIdentification of key clinical features and development of a machine learning model for screening-based detection of diabetic retinopathyhttps://www.pharmaradar360.com/article/copanlisib-in-combination-with-nivolumab-formicrosatellite-stable-colorectal-can-63b51af751429b79Pharma Surgeen2026-07-23T00:00:00.000ZCopanlisib in combination with nivolumab formicrosatellite stable colorectal cancer: a phase 1/2 trialhttps://www.pharmaradar360.com/article/oncology-drug-development-in-the-uk-analysis-of-the-past-25-years-and-focus-on-t-efdd935b993df169Pharma Surgeen2026-07-23T00:00:00.000ZOncology drug development in the UK: analysis of the past 25 years and focus on the 2026 reboot of the clinical trial regulatory frameworkhttps://www.pharmaradar360.com/article/dual-benefit-of-esketamine-based-opioid-free-anesthesia-on-postoperative-pain-an-82820abbeec4ab4fPharma Surgeen2026-07-23T00:00:00.000ZDual benefit of esketamine-based opioid-free anesthesia on postoperative pain and mental health outcomes in patients undergoing bariatric surgery: a randomized controlled trialhttps://www.pharmaradar360.com/article/a-12-week-study-on-the-effects-of-betahistine-an-h3-antagonist-h1-agonist-on-cog-29dba3b6626a0327Pharma Surgeen2026-07-23T00:00:00.000ZA 12-week study on the effects of betahistine (an H₃ antagonist/H₁ agonist) on cognitive functions in schizophrenia patients treated with olanzapine.https://www.pharmaradar360.com/article/malignant-self-regard-grit-and-perfectionism-a-construct-validation-effort-with-c40f37e107f8f955Pharma Surgeen2026-07-23T00:00:00.000ZMalignant self-regard, grit, and perfectionism: A construct validation effort with significant clinical implications.https://www.pharmaradar360.com/article/supplemental-material-for-large-language-models-detect-amplified-abstract-interp-e6e38a9191101119Pharma Surgeen2026-07-23T00:00:00.000ZSupplemental Material for Large Language Models Detect Amplified Abstract Interpretation in Trait Anxietyhttps://www.pharmaradar360.com/article/evolutionary-psychiatry-in-clinical-training-findings-from-a-workshop-based-educ-b955232572b894caPharma Surgeen2026-07-23T00:00:00.000ZEvolutionary psychiatry in clinical training: findings from a workshop-based educational evaluationhttps://www.pharmaradar360.com/article/correction-clinical-genetic-and-bioinformatic-insights-into-a-novel-lhb-variant-9a1ebe6aff4f4bacPharma Surgeen2026-07-23T00:00:00.000ZCorrection: Clinical, Genetic, and Bioinformatic Insights into a Novel LHB Variant in Isolated Luteinizing Hormone Deficiency: A Case Reporthttps://www.pharmaradar360.com/article/hermeneutic-burden-and-clinical-responsibility-a-response-to-sparrow-et-al-on-ex-bcdabffa8bcf7957Pharma Surgeen2026-07-23T00:00:00.000Z“Hermeneutic burden” and clinical responsibility: a response to Sparrow et al. on explanation and machine learninghttps://www.pharmaradar360.com/article/glp-1-receptor-agonists-and-suicidal-ideation-behavior-subject-level-analysis-of-e1d8c8ba1041ab82Pharma Surgeen2026-07-23T00:00:00.000ZGLP-1 receptor agonists and suicidal ideation/behavior: subject-level analysis of clinical trialshttps://www.pharmaradar360.com/article/factors-affecting-pharmacokinetics-and-dosing-strategies-of-polymyxin-b-in-multi-8645ef0b2f761c40Pharma Surgeen2026-07-23T00:00:00.000ZFactors Affecting Pharmacokinetics and Dosing Strategies of Polymyxin B in Multidrug-resistant Gram-negative Infected Patients with Renal Impairment: A Systematic Review with Expert Opinionhttps://www.pharmaradar360.com/article/beyond-coverage-expansion-exploring-persistent-barriers-to-cgm-utilization-in-th-d594712ef5283fc5Pharma Surgeen2026-07-23T00:00:00.000ZBeyond Coverage Expansion: Exploring Persistent Barriers to CGM Utilization in the Clinical Environmenthttps://www.pharmaradar360.com/article/effects-of-silica-infused-with-gold-silver-platinum-on-the-hepatitis-b-drug-ente-580cdf865fab5a32Pharma Surgeen2026-07-23T00:00:00.000ZEffects of Silica Infused with Gold/Silver/Platinum on the Hepatitis B Drug Entecavir by Theoretical Investigationhttps://www.pharmaradar360.com/article/immune-checkpoint-inhibitor-based-chemotherapy-for-granulocyte-colony-stimulatin-97103b623f0b05d2Pharma Surgeen2026-07-23T00:00:00.000ZImmune checkpoint inhibitor-based chemotherapy for granulocyte-colony stimulating factor-producing advanced esophageal squamous cell carcinoma: a report of three caseshttps://www.pharmaradar360.com/article/severe-pancreatic-exocrine-insufficiency-presenting-with-hypoalbuminemia-anasarc-48f39e67e598817cPharma Surgeen2026-07-23T00:00:00.000ZSevere pancreatic exocrine insufficiency presenting with hypoalbuminemia, anasarca, and pulmonary edema in a patient with prior gastrectomy and suspected immunoglobulin G4-related pancreatobiliary diseasehttps://www.pharmaradar360.com/article/abstracts-of-the-63rd-annual-symposium-of-the-international-society-for-clinical-e014e67c2ae656caPharma Surgeen2026-07-23T00:00:00.000ZAbstracts of the 63rd Annual Symposium of the International Society for Clinical Electrophysiology of Vision (ISCEV 2026), Sydney, Australiahttps://www.pharmaradar360.com/article/increased-group-2-innate-lymphoid-cell-ilc2-activity-in-pediatric-familial-medit-bc5ad2719d29982dPharma Surgeen2026-07-23T00:00:00.000ZIncreased group 2 Innate lymphoid cell (ILC2) activity in pediatric familial mediterranean fever patients with spondyloarthropathyhttps://www.pharmaradar360.com/article/integrated-bioinformatic-evaluation-unveils-a-cellular-senescence-gene-signature-b21e81973b82fbdcPharma Surgeen2026-07-23T00:00:00.000ZIntegrated bioinformatic evaluation unveils a cellular senescence gene signature as a poor prognostic factor in hepatocellular carcinomahttps://www.pharmaradar360.com/article/cost-effectiveness-analysis-of-chemoradiotherapy-compared-to-surgery-in-patients-9e8c1d126b58e49aPharma Surgeen2026-07-23T00:00:00.000ZCost-effectiveness analysis of chemoradiotherapy compared to surgery in patients with stage I esophageal squamous cell carcinoma in Japanhttps://www.pharmaradar360.com/article/real-world-study-of-effectiveness-and-safety-compared-among-isavuconazole-amphot-c4f6447f0527b33fPharma Surgeen2026-07-23T00:00:00.000ZReal-world study of effectiveness and safety compared among isavuconazole, amphotericin B, and voriconazole in invasive mold disease patientshttps://www.pharmaradar360.com/article/synthesis-of-clinical-practice-guidelines-and-recommendations-for-breast-cancer-8df8c7ac4ac6c3f4Pharma Surgeen2026-07-23T00:00:00.000ZSynthesis of clinical practice guidelines and recommendations for breast cancer survivorship care: a systematic reviewhttps://www.pharmaradar360.com/article/real-world-insights-into-bone-marrow-carcinomatosis-in-metastatic-breast-cancer-394ecb82a20a8a2aPharma Surgeen2026-07-23T00:00:00.000ZReal-world insights into bone marrow carcinomatosis in metastatic breast cancer: a retrospective analysis from two large university breast cancer centershttps://www.pharmaradar360.com/article/peripheral-blood-inflammatory-biomarkers-and-response-to-vagus-nerve-stimulation-5774debcd48bcce6Pharma Surgeen2026-07-23T00:00:00.000ZPeripheral blood inflammatory biomarkers and response to vagus nerve stimulation in pediatric drug-resistant epilepsy: A retrospective cohort studyhttps://www.pharmaradar360.com/article/ocular-biometry-in-isolated-versus-disease-associated-high-myopia-in-children-an-189eac8be1f478e8Pharma Surgeen2026-07-23T00:00:00.000ZOcular biometry in isolated versus disease-associated high myopia in children and adolescents: A retrospective observational studyhttps://www.pharmaradar360.com/article/code-clinic-a-framework-to-promote-health-data-quality-and-best-practices-for-ho-d3110588847790c5Pharma Surgeen2026-07-23T00:00:00.000ZCODE.Clinic: A Framework to Promote Health Data Quality and Best Practices for Hospital Clinical Codinghttps://www.pharmaradar360.com/article/unraveling-scp-spg46-scp-clinical-genetic-and-neuroimaging-features-2d0b538f558a5113Pharma Surgeen2026-07-23T00:00:00.000ZUnraveling <scp>SPG46</scp> : Clinical, Genetic, and Neuroimaging Featureshttps://www.pharmaradar360.com/article/association-between-dinutuximab-beta-exposure-and-post-end-of-treatment-survival-e470c03899ea935cPharma Surgeen2026-07-23T00:00:00.000ZAssociation Between Dinutuximab Beta Exposure and Post‐End‐of‐Treatment Survival in Neuroblastoma: A Weighted Patient‐Level Analysis of Three Clinical Studies